A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Primary completion date changed from estimate of Dec 31, 2027 to Sep 22, 2026
    • Eligibility criteria expanded, about 56 words
    • Study description expanded, about 8 words
    • Collaborator revised
  2. Re-verified, no change to tracked fieldsv13
  3. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2027
    • Enrollment target: 14 to 15
    v12
  4. Re-verified, no change to tracked fieldsv11
  5. Primary and study completion dates: Jan 15, 2025 to Dec 31, 2025v10
Show 8 earlier versionsHide 8 earlier versions
  1. Re-verified, no change to tracked fieldsv9
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 15 to confirmed 14
    • Site details revised
    v8
  3. Primary and study completion dates: Jan 15, 2024 to Jan 15, 2025v7
  4. 2 versions Re-verified since Apr 11, 2023, no change to tracked fieldsv5-v6
  5. Phase: Early Phase 1 to Phase 1v4
  6. Start date changed from estimate of Aug 30, 2022 to Aug 31, 2022v3
  7. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a clinical research study to learn if pembrolizumab in combination with lenvatinib can help to control pancreatic ductal adenocarcinoma.
Trial Details
NCT Number NCT05273554
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Tumor, Adenocarcinoma
Related terms Adenocarcinoma, Neoplasms
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov